|
30 Mar 2022 |
Sangamo Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of Investigational CAR-Treg Cell Therapy TX200 in Kidney Transplantation
|
|
30 Mar 2022 |
Alpha Cognition Announces Positive Data from Pre-Clinical Studies of ALPHA-0602 (Progranulin) for Amyotrophic Lateral Sclerosis (ALS)
|
|
30 Mar 2022 |
Angiocrine Bioscience Announces First Patient Dosed in Pivotal Phase 3 Clinical Trial of AB-205 in Patients with Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation (E-CELERATE) and Completion of Series B Financing
|
|
29 Mar 2022 |
IN8bio Presents Clinical Update from the Ongoing Phase 1 Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant
|
|
29 Mar 2022 |
European Medicines Agency Commences Review of Novel Gene Therapy Candidate Etranacogene Dezaparvovec for People with Hemophilia B
|
|
29 Mar 2022 |
Immorna Biotherapeutics, Inc. Receives IND Clearance to Conduct FIH Study of JCXH-211, the First-in-Class Self-replicating mRNA
|
|
29 Mar 2022 |
MaaT Pharma Announces First Patient Dosed in Phase 3 ‘ARES’ Trial Evaluating MaaT013 in Patients with Acute Graft-vs-Host-Disease
|
|
29 Mar 2022 |
Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
|
|
24 Mar 2022 |
CARsgen Announces First Patient Enrollment in the Confirmatory Phase II Clinical Trial of CT041 in China
|
|
24 Mar 2022 |
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MUC5AC for Treatment of Muco-Obstructive Lung Diseases
|
|
23 Mar 2022 |
TC BioPharm Receives MHRA and Research Ethics Committee Approvals to Initiate Phase 2B/3 Clinical Trials for the Treatment of Acute Myeloid Leukemia
|
|
23 Mar 2022 |
StemCyte, a leading regenerative cell therapy company, has submitted its application for a biologics license (BLA) for its allogeneic umbilical cord hematopoietic progenitor cell product "HPC-Cord Blood", to the US FDA
|
|
23 Mar 2022 |
Silence Therapeutics and Mallinckrodt Announce Submission of Clinical Trial Application for SLN501
|
|
23 Mar 2022 |
4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell Carcinoma
|
|
22 Mar 2022 |
Aligos Discontinues Development of its Antisense Oligonucleotide Drug Candidate ALG-020572 in Subjects with Chronic Hepatitis B and Pivots Internal Strategic Emphasis to its Small Molecule Portfolio
|
|
22 Mar 2022 |
AlloVir Initiates Global Phase 3 Registrational Study of Posoleucel for Prevention of Life-Threatening Viral Infections from Six Common Viruses in High-Risk, Allogeneic Hematopoietic Cell Transplant Patients
|
|
16 Mar 2022 |
Iovance Biotherapeutics’ Investigational New Drug Application (IND) Allowed to Proceed for TALEN®-Edited Tumor Infiltrating Lymphocyte (TIL) in Unresectable or Metastatic Melanoma and Stage III or IV Non-Small Cell Lung Cancer (NSCLC)
|
|
16 Mar 2022 |
Kairos Pharma Receives FDA Approval of Investigational New Drug (IND) Application for Its Phase 1 Clinical Trial of KROS 201 for the Treatment of Glioblastoma; Announces New Patent for KROS 401
|
|
16 Mar 2022 |
Ossium Health Announces FDA Clearance of its Investigational New Drug Application for Treatment of Perianal Fistulizing Crohn’s Disease
|
|
16 Mar 2022 |
Nutcracker Therapeutics Raises $167 Million in Series C Financing to Advance its mRNA Therapeutics and First-of-its-Kind Biochip-based Manufacturing Platform
|
|
16 Mar 2022 |
Wugen Announces First Patient Dosed in Phase 1/2 Trial of WU-CART-007 for the Treatment of Patients with R/R T-ALL/LBL
|
|
16 Mar 2022 |
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-RAGE for Treatment of Asthma
|
|
10 Mar 2022 |
Urovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902
|
|
08 Mar 2022 |
TC BioPharm Announces Positive Phase 1b/2a Data in Late-Stage Acute Myeloid Leukemia Patients Treated with Allogeneic Gamma Delta T Cells
|
|
08 Mar 2022 |
Hope Biosciences’ Cell Therapy Shown Safe, Beneficial for Rheumatoid Arthritis
|
